{"id":"W4402766756","doi":"10.1016/j.eclinm.2024.102838","title":"Advancing patient-centric care: integrating patient reported outcomes for tolerability assessment in early phase clinical trials – insights from an expert virtual roundtable","year":2024,"lang":"en","type":"review","venue":"EClinicalMedicine","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Canada","funders":"Janssen Pharmaceuticals; National Institute for Health Research Applied Research Collaboration West; MSD K.K.; Genentech; Chugai Pharmaceutical; Agency for Healthcare Research and Quality; Centers for Disease Control and Prevention; National Institutes of Health; Shionogi; Astellas Pharma; Eisai; Cancer Research UK; National Eye Institute; Seagen; National Institute for Health and Care Research; Medical Research Council; Verily Life Sciences; Department of Health and Social Care; MacroGenics; Imperial Experimental Cancer Medicine Centre; Anthony Nolan; Massachusetts Medical Society; Sarcoma UK; National Cancer Institute; Gilead Sciences; Yale University; GlaxoSmithKline; UK Research and Innovation; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Amgen; Birmingham Biomedical Research Centre; Pfizer; Astex Pharmaceuticals; Pfizer Pharmaceuticals; American Heart Association","keywords":"Medicine; Tolerability; Clinical trial; Patient care; Phase (matter); Medical physics; Intensive care medicine; Alternative medicine; Nursing; Internal medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.2699859,0.001084645,0.002603445,0.003761591,0.0007428281,0.01028249,0.002755716,0.004416304,0.002876418],"category_scores_gemma":[0.2738648,0.0008887118,0.003265088,0.004004361,0.002547104,0.009806681,0.00645184,0.007797425,0.0006035256],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006997176,"about_ca_system_score_gemma":0.02036209,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002541765,"about_ca_topic_score_gemma":0.004855677,"domain_scores_codex":[0.784239,0.1971296,0.007657926,0.001747777,0.008175951,0.00104969],"domain_scores_gemma":[0.5395519,0.4175596,0.01380474,0.008735585,0.01804022,0.002307944],"domain_codex":null,"domain_gemma":"methods","domain_candidate":"methods","domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"qualitative","study_design_scores_codex":[0.0004023969,0.0001331985,0.001403364,0.03961875,0.0008721232,0.0001131131,0.002223963,0.003037741,0.0002623308,0.1087625,0.02789928,0.8152713],"study_design_scores_gemma":[0.0008925448,0.0008263633,0.006176687,0.2105201,0.00223145,0.000544942,0.002735104,0.01385145,0.001032348,0.2068244,0.5540527,0.000311867],"study_design_candidate":"qualitative","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.003290395,0.7885731,0.08019526,0.1114837,0.002920766,0.002433106,0.0003363607,0.0001712925,0.01059585],"genre_scores_gemma":[0.1192636,0.5395008,0.283096,0.0451763,0.003830309,0.006926734,0.0005602427,0.0001503909,0.001495614],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.7300141,"threshold_uncertainty_score":0.9002374,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.6343121863443338,"score_gpt":0.629434758257566,"score_spread":0.004877428086767832,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}